Breaking News, Collaborations & Alliances, Trials & Filings

Trials & Filings in Brief: January 8, 2014

BioMarin, BMS, Catalyst, Merck, NPS, Pacira, Repros, Rexahn

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I Rexahn begins solid tumor trial . . . read more Phase III Catalyst, BioMarin post positive Firdapse results . . . read more Repros’ Androxal in head-to-head testosterone trial . . . read more Phase IV Exparel performs strongly against IV PCA opioid . . . read more Filings EMA accepts HCV MAA from BMS . . . read more NPS BLA accepted for hypoparathyroidism . . . read more Approvals Merck HIV treatment approved in oral suspension . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters